GTX INC /DE/ - FORM 8-K - December 17, 2012

Attached files

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 17, 2012

GTx, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-50549

62-1715807

(State or other jurisdiction of incorporation or organization)

(Commission

File Number)

(I.R.S. EmployerIdentification No.)

175 Toyota Plaza7th FloorMemphis, Tennessee

38103

(Address of principal executive offices)

(Zip Code)

Registrants telephone number, including area code: (901) 523-9700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

On
December 17, 2012, GTx, Inc. issued a press release announcing that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients,
a copy of which is furnished as Exhibit 99.1 to this Current Report.

ITEM 9.01

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

99.1

Press Release issued by GTx, Inc. dated December 17, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Site Links

Based on public records. Inadvertent errors are possible. Getfilings.com does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC.